HomeBUSINESS
BUSINESS

Otsuka Group to Invest 1 Billion Yen in Kyoto Startup, Aims to Commercialize iPS Cell-Derived Platelets
(Dec.26.2017)

Otsuka Pharmaceutical and Otsuka Pharmaceutical Factory, the two Otsuka Group companies, said on December 25 that they will invest a total of one billion yen in Megakaryon, a Kyoto-based startup developing iPS cell-derived platelets, through a third-party share allocation scheme ...
(LOG IN FOR FULL STORY)